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Abstract 
Rationale: To compare cancers detected during use of 5α-reductase inhibitors (5αRI) with 
cancers detected in untreated controls stratified for tumor size. 
Methods: Prostate biopsies were performed on 235 consecutive patients “for cause” (ele-
vated or rising PSA, positive digital rectal examination, or focal hypoechoic lesion). Fifty pa-
tients were excluded for a prior diagnosis of cancer, leaving 185 as the study group (5αRI=41, 
control=144). Patients in the 5αRI group had been treated for a mean of 3.5 years. Cancer 
was ultimately diagnosed in 114/185 patients.  
Results: Cancer was diagnosed in 31/41 (76%) of patients treated with 5αRI and 83/144 
(58%) of the control group (p=0.04). Control tumors were larger (14.3 mm) than those in 
5αRI treated patients (9.4 mm, p=0.0007). No differences in mean PSA or PSA kinetics were 
detected between groups. For tumors less than 1.0 cm, the proportion of high grade cancers 
(Gleason 7-10 and Gleason 4+3-10) was higher in 5αRI subjects than in controls (p<0.05). 
Fewer 5αRI patients had proven extracapsular extension than controls, but this difference did 
not reach statistical significance (p=0.13). Normal DNA ploidy was more likely to be diag-
nosed in the 5αRI group versus controls, but this difference was not statistically significant 
(81% vs. 65%, p=0.14). 
Conclusions: Cancers diagnosed in patients presenting “for cause” treated with 5αRI drugs 
are more likely to be de-differentiated compared to controls. However, these tumors are also 
smaller and less likely to have extracapsular extension and abnormal DNA ploidy than con-
trols. 
Key words: Prostate Cancer, Benign Prostatic Hyperplasia, 5α–reductase inhibitors, Gleason score, 
DNA ploidy, cancer staging. 
Introduction 
 Treatment  of  benign  prostatic  hyperplasia 
(BPH)  with  5α-reductase  inhibitors  (5αRI)  is  now 
widespread (1,2). The 5αRI drugs block the conver-
sion of testosterone into the more active dihydrotes-
tosterone, leading to shrinkage of androgen sensitive 
tissues in the prostate. Besides the use for treatment of 
BPH,  the  anti-androgenic  effects  of  5αRI  have  been 
extensively  explored  for  the  chemoprevention  of 
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prostate  cancer.  In  the  largest  studies  to  date,  both 
finasteride  and  dutasteride  were  associated  with  a 
decrease  in  the  overall  number  of  prostate  cancer 
cases (3,4). However, an unexpected finding was an 
increase in the rate of high grade cancer detected in 
the  5αRI  groups  compared  to  controls  and  raises 
questions about a possible association between 5αRI 
and biologically aggressive tumors (5).  
 Multiple  studies  have  demonstrated  a  strong 
association between prostate cancer size, pathologic 
grade  and  curability.  Before  the  era  of  5αRI  drugs, 
most  tumors  <  1  cm  in  size  were  of  low  Gleason 
grade, confined to the prostate, and considered “cur-
able” (6-9). Small tumors  with high Gleason grades 
and aggressive biologic behaviors were unusual. The 
motivation  for  this  study  was  the  recent  anecdotal 
observation in our practice of an unexpected number 
of small prostate cancers with high Gleason grades in 
men treated with 5αRI drugs. Therefore, the purpose 
of  this  study  was  to  retrospectively  compare  the 
characteristics  of  size  matched  cancers  in  patients 
treated  with  5αRI  vs.  a  control  group  consisting  of 
cancers in untreated patients.  
Materials and Methods 
 Between 1/1/2008 and 9/15/2010, 235 consec-
utive transrectal-ultrasound guided prostatic biopsies 
were performed by a single radiologist (FL) using a 
Hitachi  model  EUB  6000  (Hitachi  Medical  Systems, 
Terrytown, NY) with 5-7.5 MHz transducer with color 
flow Doppler. Indications for biopsy included: 1) an 
abnormal PSA (10) or digital rectal examination (DRE) 
and/or 2) a focal hypoechoic lesion detected by ul-
trasound (11,12). When a focal lesion was not visible 
but the PSA was elevated above predicted for gland 
volume,  sextant  biopsies  were  performed.  When  a 
focal hypoechoic lesion was visible, both targeted (2-3 
cores)  and  sextant  biopsies  were  performed  (13). 
Mean  tumor  size  was  calculated  by  the  formula 
(Width + Height + Length)/3 (11). Tumors were as-
signed to one of four groups based on mean tumor 
size (<5 mm, 5-9 mm, 10-15 mm, >15 mm). Tumors 
that were diagnosed only by sextant biopsies (i.e. no 
hypoechoic lesion was visible) were placed in the < 5 
mm group (9). Tumors were grouped into two size 
categories (<1.0 cm and >1.0 cm for the purposes of 
statistical  comparisons.  Retrospective  chart  review 
included DRE, PSA level and kinetics, length of time 
on 5αRI, and prostate gland volume. The pathologic 
results  included  tumor  size  in  millimeters,  Gleason 
score and extracapsular extension determined by bi-
opsies of neurovascular bundles and seminal vesicles 
(14). DNA ploidy was obtained and  considered ab-
normal if tetraploid and aneuploid phases were de-
tected (15,16).  
Statistical Analysis 
 For  all  statistical  analysis  results  reported, 
two-sided p-values of 0.05 or less were considered to 
indicate  statistical  significance.  Two-sample  t-tests, 
ANOVA,  Wilcoxon-Mann-Whitney  tests  and  Krus-
kal-Wallis tests were conducted for continuous varia-
bles, and Chi-square tests or Fisher’s exact tests for 
associations  were performed for contingency tables. 
Relative  risks  were  used  to  compare  the  risks  of 
high-grade  cancer  or  abnormal  pathologic  results 
between the 5αRI treated group and controls. For our 
study, Mantel-Haenszel estimates adjusting for tumor 
size were used to calculate all relative risks and asso-
ciated  confidence  intervals;  for  other  5αRI  related 
studies we considered, logarithm transformation was 
used to calculate the confidence intervals of relative 
risks. 
RESULTS 
 Study  group:  Of  the  235  patients  who  under-
went prostatic biopsies during the study period, 50 
were excluded due to a previous diagnosis of prostate 
cancer. Of the remaining 185 subjects, 41 were being 
treated with a 5αRI at the time of biopsy (21 on finas-
teride alone, 12 on dutasteride alone, and 8 on both), 
and 144 were not. Prostate cancer was diagnosed in a 
total of 114 of the 185 subjects, and these 114 patients 
constitute the study group. When stratified for 5αRI 
use,  31/41  (76%)  of  patients  treated  with  5αRI  and 
83/144  (58%)  of  the  control  group  had  cancer 
(p=0.04).  Among  the  31  5αRI  treated  subjects  with 
cancer,  the  mean  duration  (standard  deviation)  of 
5αRI use was 3.5 (2.3) years. The treatment durations 
were not significantly different between subjects with 
different tumor sizes [p=0.53].  
 Patient ages in the 5αRI and control groups were 
not statistically different, with a mean (standard de-
viation) of 66.5 (8.6) years and 65.8 (8.8) years, respec-
tively [p=0.70]. Gland volumes of subjects in the 5αRI 
group were significantly larger than controls, with a 
mean (standard deviation) 53.7 (30.4) and 45.4 (24.3) 
cubic centimeters, respectively [p=0.13].  
 Tumor  sizes:  The  distribution  of  tumor  sizes 
between  groups  was  significantly  different,  with 
larger tumor diameters found in controls (14.3 [7.0] 
mm) vs. the 5αRI subjects (9.4 [4.0] mm) [p=0.0007]. In 
particular, there was a significantly higher proportion 
of small prostate cancers (< 1 cm) in the 5αRI group 
when compared to controls, Figure 1 [64.5% vs. 26.5%, 
p=0.0002].  
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Figure 1: Tumor sizes Distributions. : Distribution of tumor size by 5αRI use. Left: Boxplot for tumor size in millimeters; 
Right: Percentage of tumor sizes <5mm, 5-9mm, 10-15mm, and >15mm. 
 
 Physical  examination  findings:  Digital  rectal 
examination overall was not as likely to be positive in 
5αRI patients (16% positive) as controls (41% positive, 
p=0.01). The likelihood of a positive DRE increased as 
tumor size increased for both 5αRI and controls. For 
tumors < 1 cm, DRE was positive in 15% and 9%, and 
in tumors ≥ 1 cm DRE positive tumors increased to 
18% and 52% for 5αRI patients and controls, respec-
tively  [p=0.04].  After  adjusting  for  tumor  sizes,  the 
relative risk of a positive DRE between 5αRI and no 
5αRI groups was 0.60, with 95% C.I. (0.23, 1.56).  
 Prostate  specific  antigen:  PSA  was  either  ele-
vated (>4) or increased in the majority of patients in 
both the 5αRI and control groups, regardless of tumor 
size (Table 1). No significant differences were detect-
ed between groups for either total PSA or PSA kinet-
ics (Figure 2).  
 Gleason scores: Table 1 summarizes the distri-
bution of histologic high grade cancer (Gleason 7-10 
or Gleason 4+3-10) stratified by tumor size and 5αRI 
use. Overall, patients on 5αRI drugs diagnosed with 
cancer had a higher likelihood of having a high grade 
tumor, but this difference did not quite reach statisti-
cal significance (Gleason 7-10: 77% vs. 64%, p=0.17; 
Gleason 4+3-10: 45% vs. 30%, p=0.13). For small (< 1 
cm)  tumors,  the  proportion  of  high  grade  cancers 
(Gleason 7-10 and Gleason 4+3-10) was higher than in 
controls  [85%  vs.  27%  (p=0.0002)  and  55%  vs.  5% 
(p=0.0003), respectively].  
 Relative risk of high grade prostate cancer: The 
relative risk of high-grade cancer for 5αRI patients in 
our study is presented in Table 2 along with the re-
sults of other trials examining 5αRI use in chemopre-
vention. The studies listed include: Finnish Prostate 
Cancer Screening Trial (17), Prostate Cancer Preven-
tion  Trial  (PCPT)  (3),  Radical  Prostatectomy  (RP) 
Cases of PCPT (18) and Effect of Dutasteride on the 
Risk of Prostate Cancer (REDUCE) (4). For the relative 
risks  of  Gleason  7-10  and  associated  confidence  in-
tervals, our result of 1.54 with 95% C.I. (1.06, 2.24) was 
consistent with those from the Finnish study, 7-year 
PCPT, RP cases of PCPT, as well as REDUCE at 3-4 
years. Our relative risk of Gleason 4+3 to 10 was 2.84 
with 95% C.I. (1.28, 6.27) was also similar to the rela-
tive risk of RP cases of PCPT (where only results of 
Gleason 8-10 are available), and similar to results from 
the REDUCE study (3-4 years). 
 Extracapular  extension:  Analysis  of  systematic 
biopsy was available in 7/31 (23%) of 5αRI subjects, 
and  45/83  (54%)  of  controls  (p=0.003).  Among  pa-
tients whose systematic biopsy results were available, 
a higher proportion of control patients had positive 
extracapsular  extension,  but  this  difference  did  not 
quite  meet  statistical  significance  (14%  vs.  44%, 
p=0.13,  5αRI  and  control  subjects  respectively).  In 
particular, for tumor size ≥1 cm, 0/5 of 5αRI subjects  Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
125 
and  20/42  (48%)  of  non-5αRI  subjects  had  positive 
ECE (p=0.06).  
 DNA  Ploidy:  Analysis  of  DNA  ploidy  was 
available in 26/31 (84%) of 5αRI subjects, and 75/83 
(90%) of controls. The remaining 13 patients had in-
sufficient  tissue  for  evaluation.  The  proportion  of 
cancers  with  normal  DNA  in  the  5αRI  group  was 
higher  than  in  controls,  but  this  difference  was  not 
statistically significant [81% vs. 65%, p=0.14, Table 2]. 
Adjusting for tumor sizes, the relative risk of abnor-
mal DNA ploidy in the 5αRI group patients was 0.73 
with 95% C.I. (0.27, 2.02). 
 
 
Figure 2: PSA kinetics. Distribution of last PSA measurement (left) and PSA measurement change (right) by 5αRI use and 
tumor size. 
 
Table 1: PSA Kinetics and Gleason Scores of Prostate Cancers. 
TRUS Tumor Size  Group  1st PSA ≥ 4 or change > 
0 
PSA Change Medi-
an (Range) 
Gleason 7-10  Gleason 4+3 to 10  Total 
<1 cm   5αRIs  18 (90%)  0.8 (0.2)  17 (85.0%)  11 (55.0%)  20 
No 5αRIs  20 (90.9%)  1.5 (0.7)  6 (27.3%)  1 (4.5%)  22 
≥1 cm   5αRIs  11 (100%)  1.3 (0.7)  7 (63.6%)  3 (27.3%)  11 
No 5αRIs  55 (90.2%)  1.3 (0.2)  47 (77.0%)  24 (39.3%)  61 
Combined   5αRIs  29 (93.5%)  1.3 (0.2)  24 (77.4%)  14 (45.2%)  31 
No 5αRIs  75 (90.4%)  1.5 (0.2)  53 (63.9%)  25 (30.1%)  83 
Subtotal  104 (91.2%)  1.3 (0.2, 21)  77 (67.5%)  39 (34.2%)  114 
 
Table 2: Relative Risk of High-Grade Cancer in 5αRI patients. 
Study  Relative Risk (95% C.I.) 
Gleason 7-10 vs. Gleason ≤ 6  Gleason 4+3-10 vs. Gleason ≤ 3+4 
1. Current study  1.54 (1.06, 2.24)  2.84 (1.28, 6.27) 
2. Finnish study17  1.59 (1.01, 2.50)  - 
3. PCPT (All Cancer)3  1.69 (1.46, 1.96)  2.43 (1.75, 3.36)* 
4. PCPT (RPs)18  1.68 (1.30, 2.17)  3.26 (1.87, 5.69)* 
5. REDUCE (1-2 years)4  1.09 (0.91, 1.31)  1.19 (0.81, 1.75) 
6. REDUCE (3-4 years)4   1.67 (1.21, 2.34)  5.09 (2.27, 11.40) 
7. REDUCE (1-4 years)4  1.22 (1.04, 1.42)  1.68 (1.21, 2.34) 
*: Relative risk between Gleason 8 to 10 vs. Gleason ≤ 7.  Journal of Cancer 2012, 3 
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Table 3: Tumor Characteristics. 
    Extracapsular extension  DNA ploidy 
Tumor Size  Group  Positive  Total  Normal   Total 
<1 cm   5αRIs  1   2  14 (77.8%)  18 
No 5αRIs  0  3  14 (82.4%)  17 
≥1 cm  5αRIs  0  5  7 (87.5%)  8 
No 5αRIs  20 (47.6%)  42  35 (60.3%)  58 
Combined   5αRIs  1 (14.3%)  7  21 (80.8%)  26 
No 5αRIs  20 (44.4%)  45  49 (65.3%)  75 
Subtotal  21 (40.4%)  52  70 (69.3%)  101 
 
 
Discussion 
 The randomized controlled trials investigating 
the  potential  chemopreventive  attributes  of  5αRI 
drugs published to date were designed primarily to 
detect a difference in the incidence of prostate cancer 
in a large population treated with 5αRI drugs. As a 
result,  routine  biopsies  performed  at  fixed  time  in-
tervals (without a particular clinical indication) were a 
critical component of the trial design. The results of 
these timed biopsies demonstrated a decrease in the 
overall  number  of  cancers  detected  in  5αRI-treated 
subjects  compared  to  untreated  controls.  This  de-
creased number of detected cancers led the authors to 
conclude  that  5αRI  drugs  were  chemopreventive 
against prostate cancer. By way of contrast, our study 
is a retrospective analysis of a series of prostatic biop-
sies  performed  for  specific  clinical  indications  (an 
abnormal  physical  examination,  rising  or  abnormal 
PSA, or a hypoechoic lesion detected at ultrasound), 
i.e. “for cause.” Therefore, the focus of our study is on 
those  patients  that  already  have  met  the  criteria  to 
undergo prostatic biopsy, not an epidemiologic study 
of the effect of 5αRI treatment on a population. In this 
setting, the positive biopsy rate was slightly higher for 
patients treated with 5αRI when compared to controls 
(76% vs. 58%, p=0.04). We believe that biopsying “for 
cause” such as in this study, is representative of most 
clinical  practices,  and  is  best  used  to  inform  physi-
cians  and  patients  when  management  decisions  are 
being  made.  Interestingly,  in  the  two  randomized 
studies of 5αRI for chemoprevention of prostate can-
cer published to date (PCPT and REDUCE), biopsies 
performed "for cause” found no significant difference 
in  prostate  cancer  detection  rates  between  groups 
(3,4).  
 Assuming that treatment of a population with 
5αRI decreases the  number of cancers detected, the 
overall salutatory effect of this result on a population 
bears  close  scrutiny  in  light  of  other  data  from  the 
trials and the results of this study. Prior to the 5αRI 
era, virtually all small (<1cm) prostate cancers were of 
low  histologic  grade,  only  rarely  had  extracapsular 
extension, and were highly curable (6-9, 11,12). Prior 
pathologic studies strongly suggest that 5αRI drugs 
either shrink or inhibit the growth of many prostate 
cancers (18,19). The results of our study support this 
hypothesis--65%  of  patients  treated  with  5αRI  had 
tumors <1cm as compared to only 27% in untreated 
controls.  The  question  that  remains  is  whether 
shrinking  or  inhibiting  tumor  growth  ultimately 
changes  biologic  behavior.  In  the  absence  of  a 
long-term  longitudinal  randomized  controlled  trial, 
examination  of  surrogate  markers  of  tumor  aggres-
siveness lead to a mixed picture. For example, in this 
study, Gleason scores were higher in patients treated 
with  5αRI  compared  to  controls.  This  finding  was 
even  more  dramatic  in  small  tumors  where  85%  of 
patients  in the 5αRI group were found to  have ag-
gressive tumors (Gleason 7-10) compared to 27% in 
the control group. The relative risk of having an ag-
gressive tumor in this study was 1.54, a comparable 
result to other studies where this ranged from 1.1-1.7 
(Table 2). Thus, while the overall number of tumors 
may be decreased, the histologic aggressiveness of the 
remaining tumors appears to be increased.  
 Questions have been raised as to  whether the 
high  grade  cancers  detected  during  PCPT  and 
REDUCE  were  a  result  of  artifactual  morphologic 
changes that could result in an over-estimation of the 
biologic  potential  of  high-grade  cancers  in  patients 
treated with 5 alpha-reductase inhibitors (20). Lucia, 
et al. evaluated the pathology of cancers found during 
PCPT and concluded that finasteride did not induce 
histomorphologic changes in prostate cancer, but may 
have contributed to the increase in high-grade cancers 
(18). Civantos, et al. observed that finasteride could 
induce foci of low grade prostate cancer to resemble 
high grade cancer (21). In response to this controver-
sy,  the  FDA  Oncologic  Drugs  Advisory  Committee  Journal of Cancer 2012, 3 
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had the histopathology from the PCPT and REDUCE 
trials re-evaluated by multiple urologic pathologists. 
Results  of  this  analysis  demonstrated  that  insignifi-
cant  histopathologic  differences  were  detected  be-
tween  cancers  in  patients  treated  with  5  al-
pha-reductase  inhibitors  and  placebo,  and  in-
tra-observer  variability  between  Gleason  scores 
among pathologists was low (22,23). 
 The association of low volume tumors and high 
Gleason  scores  found  in  this  study  most  likely  is  a 
reflection of the time our patients had been on 5αRI 
drugs prior to diagnosis (mean 3.5 years). Despite the 
fact that our study is limited by data collection at a 
single  time  point,  the  longitudinal  data  from  other 
studies demonstrates similar results in patients who 
have been on 5aRI drugs for > 4 years. For example, a 
higher proportion of high grade cancers were detect-
ed in the later data (but not at earlier time points) in 
the Finnish (17) and REDUCE (4) studies. Throughout 
the seven years of the PCPT (3) high grade cancers 
occurred. However the end of study biopsies at year 7 
discovered 38% (211/557) of these high grade cancers 
(23). This raises the possibility that 5αRI drugs selec-
tively inhibit the growth of hormonally sensitive low 
grade cancers by reducing the levels of intracellular 
dihydrotestosterone within the prostate. In the case of 
high grade or heterogeneous cell populations, 5aRIs 
may selectively allow growth of only the hormonal 
refractory high grade components.  
 Besides Gleason score, other markers of biologic 
activity include extracapsular extension of tumor and 
tumor ploidy (14,15,16). In this study, the risk of ex-
tracapsular extension was most dependent on tumor 
size rather than Gleason score. In fact, the overall risk 
of  extracapsular  extension  was  less  in  5αRI  treated 
patients  vs.  untreated  controls,  likely  reflecting  the 
smaller tumor size in 5αRI patients. The etiology of 
decreased extracapsular extension in this series may 
be similar to earlier studies where adjuvant treatment 
of  large  prostate  cancers  prior  to  radiation  therapy 
with  androgen  deprivation  shrunk  tumors  and  de-
creased overall mortality (24,25). Based on the results 
of this study, it could be argued that 5αRI is protective 
against extracapsular invasion in patients ultimately 
diagnosed with cancer, despite higher Gleason scores. 
The  other  marker  of  aggressive  biologic  behavior 
examined in this study, tumor ploidy, demonstrated a 
more  normal  DNA  appearance  in  5αRI  treated  pa-
tients vs. controls, but this difference was not statisti-
cally significant (p=0.14). Therefore, it appears as if 
patients treated with 5αRI who are eventually proven 
to have prostate cancer tend to have higher grade (but 
smaller) tumors with  less  evidence of extracapsular 
extension vs. controls, and more normal (but not sta-
tistically significant) appearing DNA. These findings 
correlate with the findings of the PCPT where high 
grade cancers were associated with lower surrogate 
findings of tumor aggression in patients treated with 
Finasteride  (18).  Whether  this  translates  into  a  sur-
vival difference compared to untreated prostate can-
cer remains to be seen. 
 The main limitation of this study is the retro-
spective consecutive case-series design and the lack of 
randomized controlled data. However, while this is a 
weakness  in  determining  the  impact  of  5αRI  treat-
ment on a population, it is advantageous when ap-
plying  the  findings  to  a  clinical  practice  where  the 
target population is patients who have undergone a 
positive  biopsy  and  are  being  treated  with  5αRI 
drugs.  An  additional  limitation  is  our  use  of  ultra-
sound to stratify patients according to tumor size. We 
have  proven  the  accuracy  of  tumor  size  measure-
ments  using  ultrasound  in  our  practice  (11,12,14), 
however, it is unclear whether this method is gener-
alizable  to  all  practitioners.  In  the  interest  of  com-
pleteness, we have also included conglomerate data 
based  on  sextant  biopsies  similar  to  studies  where 
targeted  ultrasound  techniques  were  not  available 
(13).  The  data  on  extracapsular  extension  was  also 
obtained  using  targeted  biopsies  according  to  our 
previously published methods (14). This could lead to 
an undersampling bias since generally only tumors >1 
cm received extra-capsular biopsies. Lastly, this study 
was limited to a 32 month period and the mean dura-
tion of 5αRI use was only 3.5 years. Whether treat-
ment  with  5αRI  over  longer  time  periods  would 
change the results  is not  known, but a longer term 
study will be needed to answer these questions and 
determine any impact on survival.  
 In summary, our study and others suggest that 
prostate cancer diagnosed in patients who are treated 
with 5αRI over extended periods are associated with 
increased tumor grade, even in small tumors < 1cm. 
Extracapsular extension of cancer and abnormal tu-
mor ploidy appear to be decreased in patients on 5αRI 
drugs.  Therefore,  besides  Gleason  score,  the  other 
surrogate  markers  of  tumor  aggressiveness  suggest 
that small tumors (even if high grade) in 5αRI-treated 
patients may still be low risk if detected when small. 
This information suggests the need for an aggressive 
screening  strategy  for  patients  who  are  expected  to 
remain on 5aRI drugs for long time periods. 
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